Extracellular PHF-tau modulates astrocyte mitochondrial dynamics and mediates neuronal connectivity.

Publication date: Mar 24, 2025

Tau is an intracellular protein that plays a crucial role in stabilizing microtubules. However, it can aggregate into various forms under pathological conditions and be secreted into the brain parenchyma. While the consequences of tau aggregation within neurons have been extensively studied, the effects of extracellular paired helical filaments of tau (ePHF-tau) on neurons and astrocytes are still poorly understood. This study examined the effect of human ePHF-tau (2N4R) on primary cultures of rat neuroglia, focusing on changes in neurites or synapses by microscopy and analysis of synaptosome and mitochondria proteomic profiles after treatment. In addition, we monitored the behavior of mitochondria in neurons and astrocytes separately over three days using high-speed imaging and high-throughput acquisition and analysis. ePHF-tau was efficiently cleared by astrocytes within two days in a 3D neuron-astrocyte co-culture model. Treatment with ePHF-tau led to a rapid increase in synaptic vesicle production and active zones, suggesting a potential excitotoxic response. Proteomic analyses of synaptosomal and mitochondrial fractions revealed distinct mitochondrial stress adaptations: astrocytes exhibited elevated mitochondrial biogenesis and turnover, whereas neuronal mitochondria displayed only minor oxidative modifications. In a mixed culture model, overexpression of tau 1N4R specifically in astrocytes triggered a marked increase in mitochondrial biogenesis, coinciding with enhanced synaptic vesicle formation in dendrites. Similarly, astrocyte-specific overexpression of PGC1alpha produced a comparable pattern of synaptic vesicle production, indicating that astrocytic mitochondrial adaptation to ePHF-tau may significantly influence synaptic function. These findings suggest that the accumulation of PHF-tau within astrocytes drives changes in mitochondrial biogenesis, which may influence synaptic regulation. This astrocyte-mediated adaptation to tauopathy highlights the potential role of astrocytes in modulating synaptic dynamics in response to tau stress, opening avenues for therapeutic strategies aimed at astrocytic mechanisms in the context of neurodegenerative diseases.

Open Access PDF

Concepts Keywords
Astrocytes Animals
High Astrocytes
Microtubules Astrocytes
Neurodegenerative Cells, Cultured
Tauopathy Coculture Techniques
Humans
Live imaging microscopy
MAPT protein, human
Mitochondria
Mitochondria
Mitochondrial Dynamics
Neurons
Rats
Synapse
Synapses
Tau
tau Proteins
tau Proteins

Semantics

Type Source Name
pathway REACTOME Mitochondrial biogenesis
disease MESH tauopathy
disease MESH neurodegenerative diseases
pathway REACTOME Neurodegenerative Diseases
pathway REACTOME Reproduction
drug DRUGBANK Fenamole
disease MESH neurofibrillary tangles
disease MESH death
disease MESH mitochondrial dysfunction
drug DRUGBANK Calcium
disease MESH oxidative stress
pathway KEGG Endocytosis
drug DRUGBANK Oxygen
drug DRUGBANK Tretamine
drug DRUGBANK Dimethyl sulfoxide
drug DRUGBANK Phosphate ion
disease MESH hepatitis
disease MESH dissociation
drug DRUGBANK Dextrose unspecified form
drug DRUGBANK Streptomycin
drug DRUGBANK Trestolone
drug DRUGBANK Gibberellic acid
drug DRUGBANK Amino acids
drug DRUGBANK Indoleacetic acid
drug DRUGBANK Isoxaflutole
drug DRUGBANK Proline
disease MESH hypoxia
drug DRUGBANK ATP
disease MESH infection
disease MESH cognitive disorders
drug DRUGBANK Ketamine
pathway REACTOME Muscarinic acetylcholine receptors
drug DRUGBANK Acetylcholine
disease MESH neuroinflammation
disease MESH tic
pathway KEGG Proteasome
pathway REACTOME Cellular Senescence
drug DRUGBANK L-Phenylalanine
pathway REACTOME Metabolism
disease MESH syndrome
disease MESH anomalies
disease MESH autism
disease MESH neurodevelopmental disorders
disease MESH Autism Spectrum Disorders
disease MESH Alzheimer’s disease
drug DRUGBANK Guanosine
drug DRUGBANK Curcumin
disease MESH inflammation
drug DRUGBANK Coenzyme M
disease MESH memory deficits
drug DRUGBANK (S)-Des-Me-Ampa
drug DRUGBANK Activated charcoal
drug DRUGBANK Nitrazepam
disease MESH heart failure
disease MESH Huntington’s disease
pathway REACTOME Translation
disease MESH dementia
drug DRUGBANK Ilex paraguariensis leaf
disease MESH epilepsy
pathway KEGG Alzheimer disease

Original Article

(Visited 2 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *